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Beyond its possible relationship with stemness of tumor cells, CD133/promi-
nin is a highly glycosylated trans-membrane protein that correlates with tumor size, 
metastasis and clinical stage of triple negative breast cancers (TNBC), that represent 
20% of all breast tumors and have a particularly worse clinical outcome than other 
tumor subtypes [1]. The correlation between the levels of CD133 expression and the 
biology of breast tumor cells was studied in CD133low and CD133high cell subpopula-
tions isolated from MDA-MB-231 cells (ER-, PR-, HER2-). High expression of CD133 
characterizes a small percentage of cells with larger adhesion area, lower prolifera-
tion rate, higher invasion capability and increased expression of proteins involved in 
metastasis and drug resistance of breast cancers. PLC-b2 expression, that plays a cru-
cial role in malignancy of breast tumor cells [2, 3], inversely correlates with the levels 
of CD133 and has a role in inducing the CD133high cells to CD133low cells conversion. 
The forced up-regulation of PLC-b2 counteracts the invasiveness of CD133high MDA-
MB-231, suggesting that, in TNBC, the de-regulation of this PLC isozyme is responsi-
ble of the switch from an early to a mature tumoral phenotype also by reducing the 
expression of CD133. These data might contribute to identify unexplored key steps in 
TNBC malignancy, to be considered for potential therapeutic strategies. 
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